You are here
Paul Hackett's Content
1981 AJP Limbitrol
1981 AJP Limbitrol
In collections
Metadata (MODS) |
|
|---|---|
| Titles | 1981 AJP Limbitrol |
| Related Item | |
| Genre | medicine |
| Identifier | 1981jan_mar |
| Note | New light from a trusted source. Since the turn of the century, Mead johnson has earned the trust of the medical community to produce quality medications in a variety of therapeutic categories. Now, mead Johnson research efforts in psychopharmacotherapy have brough to light newmedications for depressed and anxious patients. Venturing into promising new areas of therapy is a commitment at Mead johnson. Whether producing antibiotic, anticancer, cardiovascular or psychotropic medications, we will apply out pharmaceutical expertise in new and challenging ways for the benefit of generations to come. Mead Johnson, pharmaceutical division. Research in progress points to the role of specific CNS binding sites for the bensodiazepines- often considered the most effective anxiolytic agents. Although the clinical effectiveness of the benzodiazepines is widely accepted by the medical profession, their mechanism of action is as yet unknown. Inability to define a neurophysiological or biochemical basis of anxiety has hindered the search. Current research has, however, identified specific benzodiazepine binding sites in the CNS. Various characteristics of these sites sugest that they may represent the actual sites of action of these agents. Specific tenacity of benzodiazepines to CNS binding sites. In equilibrium bindind studies on rat and human brain tissue, benzodiazepines demonstrate a high affinity for specific sites found primarily in the synaptic membrane fraction. Of the compounds tested, only benzodiazepines compete for these binding sites. Furthermore, each benzodiazepine displays a characteristic degree of affinity which closely parallels its clinical and pharmacological potency. A significant correlation has also been found between the binding affinity of a particular benxodiazepine and its anxiolytic, anticonvulsant and muscle relaxant effects in certain animal tests. Although these in vitro animal and human tissue studies do not necessarily suggest a clinical significance, further investigation of specific benzodiazepine binding sites may provide insight into the mechanism of action of these clinicaly effective anxiolytic agents. While in vitro studies cannot be interpreted to have clinical significance, these represent an attempts to explain the limbitrom clinical affiity in the treatment of moderate to severe depression and anxiety. And to the role od tricyclic antidepressants in blocking the presynaptic reuptake of neurotransmiters- believed important in the treatment of depression. The amine hypothesis, which holds that depression is associated with a deficiency of functional neurotransmitter at the synapse, is currently the most viable theory of depression. It is supported by studies on the pharmacological action of various clinically effective antidepressants. The tricyclics, for instance, have been shwon to block reuptake by the presynaptic terminals, permitting greater availabnility and prolonged action of neurotransmitters at receptor sites. This may compensate for the relative deficit of functional neurotransmitters found in depression. Selective blockade of reuptake. The amine hypothesis has been elaborated to allow for identification of subtypes of depression based on specific neurotransmitter deficiencies. It has been proposed that measurement of the metaboloite 3-methoxy-4-hydroxy-phenylglycol (MHPG) is urine may permit such a differentiation: low MHPG levels indicating a defecit of norepinephrine, and a normal or high MHPG suggesting a deficit of another neurotransmitter, probably serotonin. Current studies indicate that certain tricyclics may be more efficent in blocking norepinephrine reuptake, while others nore selectively blockade serotonin. Further investigation may lead to eventual selection of subtype= specific antidepressants on the basis of biochemical tests. Limbitrol. Dual action specific for dual symptomatology. Limbitrol contains both a benzodiazepine- specific for the symptoms of anxiety, and amitriptyline- specific for depressive symptoms. It therefore provides the agents most appropriate to relieve both symptom syndromes in the nonpsychotic patient with mixed anxiety and depression. What better rationale for prescribing limbitrol for patients who need pharmacological intervention in support of their psychotherapy. Your guide to patient management…when you decide medication is needed. How to initiate and maintain therapy. How to make each patient an informed patient |
| Abstract | benzodiazepine and amitriptyline, Mead Johnson/ Roche, artists rendering of synapses and brain in blue and red to mimic microscopy and neural imaging. framed like scientific article, many citations. Offers instructions of how to practice, not just pharmaceutical information. Seems to address fear of physician losing control to medication by saying "when you decide.." |